RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/37127

Title:	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Authors:	Cruz, C Castroviejo-Bermejo, M Gutiérrez-Enríquez, S Llop-Guevara, A Ibrahim, Y H Gris-Oliver, A Bonache, S Morancho, B Bruna, A Rueda, O M Lai, Z Polanska, U M Jones, G N Kristel, P de Bustos, L Guzman, M Rodríguez, O Grueso, J Montalban, G Caratú, G Mancuso, F Fasani, R Jiménez, J Howat, W J Dougherty, B Vivancos, A Nuciforo, P Serres-Créixams, X Rubio, I T Oaknin, A Cadogan, E Barrett, J C Caldas, C Baselga, J Saura, C Cortés, J Arribas, J Jonkers, J Díez, O O'Connor, M J Balmaña, J Serra, V View more
Issue Date:	1-May-2018
Citation:	Ann. Oncol..2018 May;(29)5:1203-1210
Abstract:	BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity.
PMID:	29635390
URI:	https://hdl.handle.net/20.500.12530/37127
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5961353.pdf		473.65 kB	Adobe PDF	View/Open